secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628280-26-031725
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath Q1 2026 revenue $25M (+26% YoY); net loss $1.1M; guides FY rev at least $100M
--------------------------------------------------------------------------------

- Total revenue $25.0M, up 26% YoY; HEPZATO KIT revenue $23.3M (+29% YoY); CHEMOSAT $1.7M (flat).
- Net loss of $1.1M vs net income $1.1M prior year; non-GAAP adjusted EBITDA $3.4M vs $7.6M.
- Cash and investments $89.3M, no debt; repurchased 316,023 shares for $3.0M in Q1.
- FY 2026 guidance: revenue at least $100M, gross margins 84-87%, positive adjusted EBITDA.
- Active centers 29; CHOPIN Phase 2 trial published in The Lancet Oncology; ESMO guideline inclusion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000162828026031725/0001628280-26-031725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000162828026031725/dcth-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-031725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer